Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells
Metrics: PDF 2701 views | HTML 15735 views | ?
Chris Shidal1,3,4, Numan Al-Rayyan2,3, Kavitha Yaddanapudi2,3, Keith R. Davis4
1Department of Pharmacology and Toxciology, University of Louisville School of Medicine, Louisville, Kentucky, USA
2Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA
3James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA
4Biotechnology Program, Indiana University, Bloomington, Indiana, USA
Keith R. Davis, email: [email protected]
Kavitha Yaddanapudi, email: [email protected]
Keywords: lunasin, melanoma, cancer stem cells, MITF, NANOG
Received: May 16, 2016 Accepted: August 13, 2016 Published: August 23, 2016
Recent studies provide compelling evidence that melanoma is initiated and maintained by a small population of malignant cells called cancer-initiating cells (CICs) that exhibit stem-cell-like properties. Observations that CICs have a distinct biology when compared to that of the bulk tumor cells and, importantly, are resistant to chemotherapies and radiation, suggest that CICs are involved in invasion, metastasis, and ultimately relapse. Lunasin, a bioactive peptide present in soybean, has both chemopreventive activity and chemotherapeutic activity against multiple cancer types. In this study, we tested the potential of Lunasin to specifically target CICs in melanoma tumor cell populations. In vitro studies using human melanoma cell lines showed that Lunasin treatment decreased the size of a subpopulation of melanoma cells expressing the surrogate CIC marker, Aldehyde Dehydrogenase, concomitant with a reduction in the ability to form colonies in soft agar assays, and reduced tumor growth in mouse xenografts. Similarly, Lunasin inhibited colony formation by isolated melanoma CICs in soft agar and reduced oncosphere formation in vitro and substantially inhibited tumor growth in mouse xenografts. Mechanistic studies revealed that Lunasin treatment of isolated melanoma CICs induced expression of the melanocyte-associated differentiation markers Tyrosinase and Microphthalmia-associated Transcription Factor concomitant with reduced expression of the stemness factor NANOG. These findings document for the first time that Lunasin has significant therapeutic activity against melanoma by specifically targeting melanoma CICs, and inducing a more differentiated, non-CIC phenotype. Thus, Lunasin may represent a novel therapeutic option for both chemoresistant and advanced metastatic melanoma management.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.